cdmo.directory
← Compare landing

Boston Institute of Biotechnology, LLC vs Minaris Advanced Therapies

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/bostonbib/wuxi-advanced-therapies

CategoryBoston Institute of Biotechnology, LLCMinaris Advanced Therapies
Listed sitecdmocdmo
SummaryFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.Pure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
Services
  • Cell-Line Development
  • Process Development
  • CMC Analytical Development
  • Formulation Development
  • Stability Testing & Storage
  • Quality Control Testing
  • Upstream Processing
  • Downstream Processing
  • Recombinant Protein Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Microbial Fermentation
  • Vaccine Manufacturing
  • AAV Manufacturing
  • Viral Vector Manufacturing
  • Vial Filling
  • Lyophilization (Freeze Drying)
  • Prefilled Syringe (PFS) Filling
  • Sterile Fill-Finish & Aseptic Manufacturing
  • Technology Transfer
  • CMC Regulatory Submission Support
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Cell Therapy Manufacturing
  • Autologous Cell Therapy Manufacturing
  • Allogeneic Cell Therapy Manufacturing
  • Viral Vector Manufacturing
  • AAV Manufacturing
  • Lentiviral Vector Manufacturing
  • Cell-Line Development
  • Technology Transfer
  • Process Development
  • CMC Analytical Development
  • Stability Testing & Storage
  • Quality Control Testing
  • Vaccine Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Recombinant Protein Manufacturing
Modalities
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
  • AAV / Viral Vector Platform
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • AAV / Viral Vector Platform
IndicationsData not yet provided.Data not yet provided.
Locations
  • Southborough, Southborough, Massachusetts, United States
  • Zhangjiang (P01), Shanghai, Shanghai, China
  • Lingang (IP02), Shanghai, Shanghai, China
  • Lingang (IP03), Shanghai, Shanghai, China
  • Headquarters, Southborough, Massachusetts, United States
  • Headquarters, Philadelphia, PA, United States
  • Philadelphia, Philadelphia, PA, United States
  • Allendale, Allendale, NJ, United States
  • Taufkirchen, Taufkirchen, Bavaria, Germany
  • London, London, England, United Kingdom
  • Yokohama, Yokohama, Kanagawa, Japan
  • Manufacturing & Testing, Philadelphia, PA, United States
  • Manufacturing, Allendale, NJ, United States
  • Manufacturing, Taufkirchen, Bavaria, Germany
  • Office, London, England, United Kingdom
  • Manufacturing, Yokohama, Kanagawa, Japan
  • Manufacturing & Testing, Allendale, NJ, United States
  • Manufacturing & Testing, Taufkirchen, Bavaria, Germany
  • Manufacturing & Testing, Yokohama, Kanagawa, Japan
CertificationsData not yet provided.
  • FDA · Identifier: Commercial manufacturing approval
  • EMA · Identifier: Commercial manufacturing approval
  • PMDA · Identifier: Commercial manufacturing approval
  • FDA · Identifier: FDA approval for commercial manufacturing
  • EMA · Identifier: EMA approval for commercial manufacturing
  • PMDA · Identifier: PMDA approval for commercial manufacturing
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.